In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Bristol-MyersSquibb (BMY – Research Report). The company’s shares closed yesterday at $50.12.
BristolMyersSquibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...
Results that may be inaccessible to you are currently showing.